UNSPSC 51294902: Aceprometazine

This classification denotes an antidepressant agent with the molecular formula C19H22N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 984N9YTM4Y, chemically known as ketone, 10-(2-(dimethylamino)propyl)phenothiazin-2-yl methyl but generally known as aceprometazine, which bears US NIH Compound Identifier 26035. European Medicines Agency schedules Aceprometazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05214MIG. The term ACEPROMETAZINE is an International Non-Proprietary Name.

UNSPSC 51294902 Aceprometazine is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local procurement activity under this code does not align with the abstract pharmaceutical designation. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS—solicits naloxone and safe drug deactivation systems, products that fall outside the aceprometazine scope. Seminole County is seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, supporting community health and emergency response initiatives rather than aceprometazine procurement. The contract carries a two-year initial term with a one-year renewal option and requires vendors to meet federal compliance standards including E-Verify authorization, drug-free workplace certification, and specific insurance coverages.

The code shows minimal recent activity limited to Florida at present. Seminole County issued the naloxone and drug deactivation systems IFB on July 10, 2023, with a response deadline of July 26, 2023, at 2:00 pm. Vendors must submit bids electronically through the county's e-Procurement Portal, include all shipping and delivery costs in their proposals, and provide unit pricing for each line item. The procurement does not specify set-aside designations. Potential FEMA funding introduces additional compliance requirements under the Clean Air Act and Federal Water Pollution Control Act. The significant mismatch between the code's nominal scope (aceprometazine) and the actual procurement (naloxone and harm-reduction systems) suggests the code may be tagged incorrectly in the county's system or used as a catch-all for pharmaceutical and medical-device procurements outside the core taxonomy.